The global genomic biomarker market describes genetic variations that can be used as an indicator of normal biological as well as pathogenic processes or pharmacological responses to a therapeutic intervention. Genomic biomarkers provide invaluable insights into cancer biology by revealing molecular characteristics of tumors to guide treatment selection. Genomic biomarkers have revolutionized the diagnosis, prognosis, patient stratification, and treatment monitoring of cancer.
The global Genomic Biomarker Market is estimated to be valued at US$ 6,072.92 Million in 2024 and is expected to exhibit a CAGR Of 7.1% over the forecast period of 2024 To 2030.
Genomic biomarkers are genetically inherited variations or acquired changes in DNA sequence or chromosomal abnormalities that help in better diagnosis and treatment of cancer. They help in identifying patients most likely to respond to certain anti-cancer therapies based on their genetic makeup and profile of the tumor. For example, breast cancer biomarkers like BRCA1 and BRCA2 mutations are associated with increased risk. Similarly, EGFR mutations in lung cancer predict response to targeted therapies. Technological advancements in next-generation sequencing, bioinformatics application, and dropping costs of whole genome analysis have increased clinical applications of biomarkers across different therapeutic areas. The growing prevalence of cancer and need for improved and personalized treatments is fueling demand for genomic biomarkers.
Key players operating in the genomic biomarker market are Varian Medical Systems, Elekta AB, Becton, Dickinson and Company, IsoRay, Inc., Eckert & Ziegler BEBIG, and iCAD. These players are focusing on partnerships, new product launches, and regional expansion to gain market share.
The rising global cancer burden coupled with advancements in precision oncology is a major factor driving the genomic biomarker market. Biomarker testing enables identification of patients most likely to benefit from targeted therapies, improving treatment outcomes. Furthermore, biomarkers help avoid adverse effects and unnecessary costs from treatments that may not work for a given patient.
Technological advancements like next-generation sequencing, bioinformatics applications, and lowering costs of whole genome analysis are widening the clinical applications of biomarkers across various diseases. Biomarker discovery and validation platforms enabled by such technologies are improving efficiency and accuracy of biomarker testing.
Liquid biopsy based biomarkers- Liquid biopsy analyzes blood or other body fluid samples for biomarkers like DNA, RNA, proteins rather than relying on invasive tissue biopsies. This non-invasive approach enables real-time monitoring of tumor evolution and treatment response.
Companion diagnostics- Biomarker tests are increasingly being developed and marketed along with targeted drugs to identify patients most likely to respond, thereby enhancing efficacy and safety of precision medicine approaches.
Emerging markets- Developing countries in Asia Pacific and Latin America offer significant opportunities for genomic biomarker market players due to increasing healthcare expenditures and rising cancer incidence.
New biomarker discovery- Continued research into cancer genomics and multi-omics approaches will uncover novel biomarkers with potential to improve screening, diagnosis, and treatment monitoring capabilities across different cancer types.
In conclusion, the global genomic biomarker market will experience strong growth due to rising cancer burden globally and continuous technological improvements widening clinical applications of biomarkers.
Impact of COVID-19 on Genomic Biomarker Market Growth
The outbreak of COVID-19 has significantly impacted the growth of the genomic biomarker market. During the initial phase of the pandemic, most healthcare facilities focused their resources on treating COVID-19 patients which led to postponing or canceling many non-emergency medical procedures including cancer screening and treatments. This negatively affected the demand for genomic biomarkers which are widely used in personalized cancer care for detection, diagnosis, prognosis, and monitoring treatment response. However, with rising awareness about early cancer detection being critical for better outcomes, the demand is recovering in the post-COVID period. Researchers are also exploring host genetic factors that can influence COVID-19 severity to develop biomarkers for risk prediction. This is anticipated to open new opportunities over the coming years.
Going forward, demand is expected to rise steadily as healthcare systems adapt to the new normal. Efforts are underway to utilize genomic biomarkers to gain insights into the different disease trajectories of COVID-19. Clinical trials are exploring if pre-existing biomarkers could help stratify patients according to infection risk and severity. Testing for lung cancer biomarkers is also increasing to address the backlog created during lockdowns as delayed screenings could lead to presenting at advanced stages. Telehealth is aiding continuity of care while minimizing hospital visits. Overall, while disruptions were experienced initially, genomic biomarkers are poised for steady growth supported by growing cancer burden worldwide.
Concentration of Genomic Biomarker Market by Geographical Regions
North America currently accounts for the largest share of the Global Genomic Biomarker Market in terms of value. This is attributed to factors such as the rising prevalence of cancer, growing biomarker-based diagnostic rates, robust research funding, and presence of leading market players. Within the region, the U.S. is the major revenue generator owing to a well-developed healthcare system and availability of advanced precision medicine technologies.
Asia Pacific is projected to witness the fastest growth over the forecast period supported by expanding healthcare infrastructure, increasing healthcare expenditures, rising awareness about early disease detection, and growing focus on companion diagnostics. China, Japan, and India are likely to be lucrative regional markets. Initiatives like India's National Cancer Grid are striving to improve access to genomic testing in oncology. The growing middle-class population with greater affordability for high-quality cancer care will further aid market growth in Asia Pacific.
Get more insights on this topic :